Immunodeficiency Syndromes

Harper's Textbook of Pediatric Dermatology: Third Edition

Volumn 2, Issue , 2011, Pages 1-34

  Schaffer, Julie V ^a   Paller, Amy S ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Ataxia telangiectasia; Ch diak higashi syndrome; Chronic granulomatous disease; Chronic mucocutaneous candidiasis; Complement; Hyperimmunoglobulin e syndrome; Hyperimmunoglobulin M syndromes; Hypogammaglobulinaemia; Immunodeficiency; Immunoglobulin; Leucocyte adhesion deficiency; Severe combined immunodeficiency

Indexed keywords

EID: 84880794779     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444345384.ch177     Document Type: Chapter

References (182)

1. Geha RS, Notarangelo LD, Casanova JL et al. Primary immunodefi-ciency diseases: an update from the International Union of Immunological Societies Primary Immunodefi ciency Diseases Classifi cation Committee. J Allergy Clin Immunol 2007;120:776-94.
2. Buckley RH. Primary immunodefi ciency diseases due to defects in lymphocytes. N Engl J Med 2000;343:1313-24.
3. Fischer A. Human primary immunodefi ciency diseases. Immunity 2007;27:835-45.
4. Maródi L, Notarangelo LD. Immunological and genetic bases of new primary immunodefi ciencies. Nat Rev Immunol 2007;7:851-61.
5. Mitra A, Pollock B, Gooi J. Cutaneous granulomas associated with primary immunodefi ciency disorders. Br J Dermatol 2005;153:194-9.
6. Torrelo A, Vera A, Portugues M. Perforating neutrophilic and granulomatous dermatitis of the newborn: a clue to immunodefi ciency. Pediatr Dermatol 2007;24:211-5.
7. Slatter MA, Gennery AR. An approach to the patient with recurrent infections in childhood. Clin Exp Immunol 2008;152:389-96.
8. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodefi ciencies. J Pediatr 1995;126:1-10.
9. Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
10. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008;9:759-69.
11. Lee JH, Paull TT. ATM activation by DNA double-stranded breaks through the Mre11-Rad50-Nbs1 complex. Science 2005;308:551-4.
12. Cohen LE, Tanner DJ, Schaefer HG et al. Common and uncommon cutaneous fi ndings in patients with ataxia telangiectasia. J Am Acad Dermatol 1984;10:431-7.
13. Paller AS, Massey RB, Curtis MA et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr 1991;119:917-22.
14. Khumalo NP, Joss DV, Huson SM, Burge S. Pigmentary anomalies in ataxia-telangiectasia: a clue to diagnosis and an example of twin spotting. Br J Dermatol 2001;144:369-71.
15. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA et al. Immunodefi ciency and infections in ataxia-telangiectasia. J Pediatr 2004;144:505-11.
16. Staples ER, McDermott EM, Reiman A et al. Immunodefi ciency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol 2008;153:214-20.
17. Cabana MD, Crawford RO, Winkelstein JA et al. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998;102:98-100.
18. Thompson D, Duedal S, Kirner J et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22.
19. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
20. Crawford TO, Skolasky RL, Fernandez R et al. Survival probability in ataxia telangiectasia. Arch Dis Child 2006;91:610-1.
21. Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007;81-2:129-47.
22. Lai C-H, Chun HH, Nahas SA et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004;101:15676-81.
23. Ridanpaa M, Van Eenennaam H, Pelin K et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 2001;104:195-203.
24. Brennan T, Pearson R. Abnormal elastic tissue in cartilage-hair hypoplasia. Arch Dermatol 1988;124:1411-14.
25. Notarangelo LD, Roifman CM, Giliani S. Cartilage-hair hypoplasia: molecular basis and heterogeneity of the immunological phenotype. Curr Opin Allergy Clin Immunol 2008;8:534-9.
26. Kavadas FD, Giliani S, Gu Y et al. Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. J Allergy Clin Immunol 2008;122:1178-84.
27. Toivianen-Salo S, Kajosaari M, Piilonen A, M äkitie O. Patients with cartilage hair hypoplasia have an increased risk for bronchiectasis. J Pediatr 2008;152:422-8.
28. Taskinen M, Ranki A, Pukkala E et al. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confi rms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A 2008;146A:2370-5.
29. Shiflett SL, Kaplan J, Ward DM. Ch édiak-Higashi syndrome: a rare disorder of lysosomes and lysosome related organelles. Pigment Cell Res 2002;15:251-7.
30. Anderson LL, Paller AS, Malpass D et al. Chediak-Higashi syndrome in a black child. Pediatr Dermatol 1992;9:31-6.
31. Barbosa MD, Nguyen QA, Tchernev VT et al. Identifi cation of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996;382:262-4.
32. Westbroek W, Adams D, Huizing M et al. Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. J Invest Dermatol 2007;127:2674-7.
33. Al-Khenaizan S. Hyperpigmentation in Chediak-Higashi syndrome. J Am Acad Dermatol 2003;49:S244-6.
34. Kinugawa N. Epstein-Barr virus infection in Chediak-Higashi syndrome mimicking acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1990;12:182-6.
35. Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodefi-ciency. Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol 1998;38:295-300.
36. Menasche G, Pastural E, Feldmann J et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000;25:173-6.
37. Pastural E, Barrat FJ, Dufourcq-Lagelouse R et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet 1997;16:289-92.
38. M énasch éG, Ho CH, Sanal O et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest 2003;112:450-6.
39. Enders A, Zieger B, Schwarz K et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006;108:81-7.
40. Hartley JL, Zachos NC, Dawood B et al. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy). Gastroenterology 2010;138:2388-98.
41. Eapen M, DeLaat CA, Baker KS et al. Hematopoietic cell transplantation for Ch édiak-Higashi syndrome. Bone Marrow Transplant 2007;39:411-5.
42. Trottestam H, Beutel K, Meeths M et al. Treatment of the X-linked lymphoproliferative, Griscelli and Ch édiak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer 2009;52:268-72.
43. Segal BH, Leto TL, Gallin JI et al. Genetic, biochemical, and clinical features of the chronic granulomatous disease. Medicine 2000;79:170-200.
44. Winkelstein JA, Marino MC, Johnston RB et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 2000;79:155-69.
45. Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune defi ciencies: chronic granulomatous disease and leukocyte adhesion defi ciency. Curr Opin Hematol 2007;14:29-36.
46. Rada BK, Geiszt M, Kaldi K et al. Dual role of phagocytic NADPH oxidase in bacterial killing. Blood 2004;104:2947-53.
47. Brinkmann V, Zychlinsky A. Benefi cial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007;5:577-82.
48. Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabolism underlies infl ammation in mouse chronic granulomatous disease. Nature 2008;451:211-6.
49. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol 2005;174:411-7.
50. Sedel D, Huguet P, Lebbe C et al. Sweet syndrome as the presenting manifestation of chronic granulomatous disease in an infant. Pediatr Dermatol 1994;11:237-40.
51. De Ravin SS, Naumann N, Cowen EW et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008;122:1097-103.
52. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007;148:79-84.
53. Jirapongsananuruk O, Malech HL, Kuhns DB et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. J Allergy Clin Immunol 2003;111:374-9.
54. Kang EM, Malech HL. Advances in treatment for chronic granulomatous disease. Immunol Res 2009;43:77-84.
55. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008;140:255-66.
56. Margolis DM, Melnick DA, Alling DW et al. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162:723-6.
57. Gallin JI, Alling DW, Malech HL. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22.
58. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
59. Seger RA, Gungor T, Belohradsky BH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodifi ed hematopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002;100:4344-50.
60. Del Guidice I, Iori AP, Mengarelli A et al. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol 2003;82:189-92.
61. Gungor T, Halter J, Klink A et al. Successful low toxicity haematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005;79:1596-606.
62. Malech HL, Mapels PB, Whiting-Theoblad N et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997;94:12133-8.
63. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
64. Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001;20:197-206.
65. Ahonen P, Myll ärniemi S, Sipil äI et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829-36.
66. Anonymous (Finnish-German APECED Consortium). An autoimmune disease, APECED, is caused by mutations in a novel gene featuring two PHD-type zinc-fi nger domains: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat Genet 1997;17:399-403.
67. Liston A, Lesage S, Wilson J et al. Aire regulates negative selection of organ-specifi c T cells. Nat Immunol 2003;4:350-4.
68. Aschenbrenner K, D ' Cruz LM, Vollmann EH et al. Selection of Foxp3(+ ) regulatory T cells specifi c for self antigen expressed and presented by Aire( + ) medullary thymic epithelial cells. Nat Immunol 2007;8:351-8.
69. Ryan KR, Hong M, Arkwright PD et al. Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. Clin Exp Immunol 2008;154:406-14.
70. P öntynen N, Strengell M, Sillanp ääN et al. Critical immunological pathways are downregulated in APECED patient dendritic cells. J Mol Med 2008;86:1139-52.
71. Glocker EO, Hennigs A, Nabavi M et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009;361:1727-35.
72. Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 defi-ciency and mucocutaneous fungal infections. N Engl J Med 2009;361:1760-7.
73. Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non -Candida infection: a report of the Pediatric Immunodefi ciency Collaborative Study Group. J Pediatr 1990;116:377-82.
74. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006;91:2843-50.
75. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007;370:1443-52.
76. Lindsay EA, Vitelli F, Su H et al. Tbx1 haploinsuffi ciency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 2001;410:97-101.
77. Markert ML, Hummell DS, Rosenblatt HM et al. Complete DiGeorge syndrome: persistence of profound immunodefi ciency. J Pediatr 1998;132:15-21.
78. Selim MA, Markert ML, Burchette JL et al. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol 2008;35:380-5.
79. Sj öholm AG, J önsson G, Braconier JH et al. Complement defi ciency and disease: an update. Mol Immunol 2006;43:78-85.
80. Frank MM. Complement defi ciencies. Pediatr Clin North Am 2000;47:1339-54.
81. Carneiro-Sampaio M, Liphaus BL, Jesus AA et al. Understanding systemic lupus erythematosus physiopathology in the light of primary immunodefi ciencies. J Clin Immunol 2008;28:S34-41.
82. Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both?. J Exp Med 2004;199:1295-9.
83. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor defi-ciency: biological and clinical characteristics in 235 patients. Medicine 1992;71:206-15.
84. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359:1027-36.
85. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001;161:2417-429.
86. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356:213-7.
87. Davis AE. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008;100:S7-12.
88. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008;101:279-86.
89. Cinchon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104.
90. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new fi ndings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74.
91. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor defi ciency. Am J Gastroenterol 2006;101:619-27.
92. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor defi ciency: consensus document. Clin Exp Immunol 2005;139:379-94.
93. Blanch A, Roche O, Urrutia I et al. First case of homozygous C1 inhibitor defi ciency. J Allergy Clin Immunol 2006;118:1330-5.
94. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008;121:272-80.
95. Farkas H, Varga L, Sz éplaki G et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120:e713-22.
96. Cook HT, Botto M. The complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006;2:330-7.
97. Sontheimer RD, Racila E, Racila DM. C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J Invest Dermatol 2005;125:14-23.
98. Schneider MC, Exley RM, Ram S et al. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007;15:233-40.
99. Sprong T, Roos D, Weemaes C et al. Defi cient alternative complement pathway activation due to factor D defi ciency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006;107:4865-70.
100. J önsson G, Sj öholm AG, Truedsson I et al. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 defi ciency. Rheumatology 2007;46:1133-9.
101. Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement defi ciency. J Allergy Clin Immunol 2004;113:585-93.
102. Mollnes TE, Jokiranta TS, Truedsson L et al. Complement analysis in the 21st century. Mol Immunol 2007;44:3838-49.
103. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007;370:1443-52.
104. Lindsay EA, Vitelli F, Su H et al. Tbx1 haploinsuffi ciency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 2001;410:97-101.
105. Markert ML, Hummell DS, Rosenblatt HM et al. Complete DiGeorge syndrome: persistence of profound immunodefi ciency. J Pediatr 1998;132:15-21.
106. Selim MA, Markert ML, Burchette JL et al. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol 2008;35:380-5.
107. Grimbacher B, Holland SM, Gallin JI et al. Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. N Engl J Med 1999;340:692-702.
108. Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper IgE syndromes. Pediatr Res 2009;65:32R-7R.
109. Borges WG, Hensley T, Carey JC et al. The face of Job. J Pediatr 1998;133:303-5.
110. Renner ED, Puck JM, Holland SM et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr 2004;144:93-9.
111. Zhang Q, Davis JC, Lamborn IT et al. Combined immunodefi ciency associated with DOCK8 mutations. N Engl J Med 2009;361:2046-55.
112. Engelhardt KR, McGhee S, Winkler S et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009;124:1289-302.
113. Holland SM, DeLeo FR, Elloumi HZ et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608-19.
114. Minegishi Y, Saito M, Tsuchiya S et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058-62.
115. Milner JD, Brenchley JM, Laurence A et al. Impaired T H 17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6.
116. Minegishi Y, Saito M, Morio T et al. Human tyrosine kinase 2 defi-ciency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25:745-55.
117. Chamlin SL, McCalmont TH, Cunningham BB et al. Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 2002;141:572-5.
118. Eberting CL, Davis J, Puck JM et al. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 2004;140:1119-25.
119. Freeman AF, Collura-Burke CJ, Patronas NJ et al. Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 2007;119:e1121-5.
120. Woellner C, Gertz EM, Sch äffer AA et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010;125:424-32.
121. Joshi AY, Iyer VN, Boyce TG et al. Elevated serum immunoglobulin E (IgE): when to suspect hyper-IgE syndrome: a 10-year pediatric tertiary care center experience. Allergy Asthma Proc 2009;30:23-7.
122. Hershkovitz T, Hassoun G, Indelman M et al. A homozygous missense mutation in PEPD encoding peptidase D causes prolidase defi-ciency associated with hyper-IgE syndrome. Clin Exp Dermatol 2006;31:435-40.
123. Jeppson JD, Jaffe HS, Hill HR. Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyperimmunoglobulinemia E and recurrent infections. J Pediatr 1991;118:383-7.
124. Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1995;95:771-4.
125. Bard S, Paravisini A, Avil és-Izquierdo JA et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008;144:1662-3.
126. Conley ME. Genes required for B cell development. J Clin Invest 2003;112:1636-8.
127. Grimbacher B, Sch äffer AA, Peter HH. The genetics of hypogammaglobulinemia. Curr Allergy Asthma Rep 2004;4:349-58.
128. Wood P, Stanworth S, Burton J et al. Recognition, clinical diagnosis and management of patients with primary antibody defi ciencies: a systematic review. Clin Exp Immunol 2007;149:410-23.
129. Korth äuser U, Graf D, Mages HW. Defective expression of T-cell CD40 ligand causes X-linked immunodefi ciency with hyper-IgM. Nature 1993;361:539-40.
130. DiSanto JP, Bonnefoy JY, Gauchat JF et al. CD40 ligand mutations in X-linked immunodefi ciency with hyper-IgM. Nature 1993;361:541-3.
131. Revy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AIS) defi ciency causes the autosomal recessive form of the hyper -IgM syndrome (HIGM2). Cell 2000;102:565-75.
132. Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr Opin Rheumatol 2006;18:369-76.
133. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 defi ciency: clinical, molecular, and immunological features. Immunol Rev 2005;203:48-66.
134. Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005;203:67-79.
135. Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol 2008;28:S62-6.
136. Chang MW, Romero R, Scholl PR et al. Mucocutaneous manifestations of the hyper-IgM Immunodefi ciency syndrome. J Am Acad Dermatol 1998;38:191-6.
137. Vetrie D, Vorechovsky I, Sideras P et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1992;361:226-33.
138. Tsukada S, Saffran DC, Rawlings DJ et al. Defi cient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-90.
139. Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodefi ciency and IgA defi ciency. Nat Genet 2005;37:829-34.
140. Park MA, Li JT, Hagan JB et al. Common variable immunodefi ciency: a new look at an old disease. Lancet 2008;372:489-502.
141. Bonilla FA, Geha RS. Common variable immunodefi ciency. Pediatr Res 2009;65:13-19R.
142. Ng W, Tan CL, Yeow V et al. Ecthyma gangrenosum in a patient with hypogammaglobulinemia. J Infect 1998;36:331-5.
143. Glocker E, Ehl S, Grimbacher B. Common variable immunodefi ciency in children. Curr Opin Pediatr 2007;19:685-92.
144. Cunningham-Rundles C, Bodian C. Common variable immunodefi-ciency: clinical and immunological features of 248 patients. Clin Immunol 1999;92:34-48.
145. Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol 2008;122:1038-9.
146. Halabi-Tawil M, Ruemmele FM, Fraitag S et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 2009;160:645-51.
147. Caudy AA, Reddy ST, Chatila T et al. CD25 defi ciency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007;119:482-7.
148. Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune defi ciencies: chronic granulomatous disease and leukocyte adhesion defi ciency. Curr Opin Hematol 2007;14:29-36.
149. Bunting M, Harris ES, McIntyre TM et al. Leukocyte adhesion defi-ciency syndromes: adhesion and tethering defects involving β2 integrins and selectin ligands. Curr Opin Hematol 2002;9:30-5.
150. Bauer TR, Gu YC, Creevy KE et al. Leukocyte adhesion defi ciency in children and Irish Setter dogs. Pediatr Res 2004;55:363-7.
151. Wild MK, L ühn K, Marquardt T et al. Leukocyte adhesion defi ciency II: therapy and genetic defect. Cells Tissues Organs 2002;172:161-73.
152. Kuijpers TW, van de Vijver E, Weterman MA et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 2009;113:4740-6.
153. Svensson L, Howarth K, McDowall A et al. Leukocyte adhesion defi ciency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009;15:306-12.
154. Helmus Y, Denecke J, Yakubenia S et al. Leukocyte adhesion defi-ciency II patients with a dual defect of the GDP-fucose transporter. Blood 2006;107:3959-66.
155. Kuijpers TW, van Bruggen R, Kamerbeek N et al. Natural history and early diagnosis of LAD-1/variant syndrome. Blood 2007;109:3529-37.
156. Kilic SS, Etzioni A. The clinical spectrum of leukocyte adhesion defi-ciency (LAD) III due to defective CalDAG-GEF1. J Clin Immunol 2009;29:117-22.
157. Marquardt T, Luhn K, Srikrishna G et al. Correction of leukocyte adhesion defi ciency type II with oral fucose. Blood 1999;94:3976-85.
158. Qasim W, Cavazzana-Calvo M, Davies EG et al. Allogeneic haematopoietic stem-cell transplantation for leukocyte adhesion defi ciency. Pediatrics 2009;123:836-40.
159. Bauer TR, Allen JM, Hai M et al. Successful treatment of canine leukocyte adhesion defi ciency by foamy virus vectors. Nat Med 2008;14:93-7.
160. Fischer A, Le Deist F, Hacein-Bey-Abina S et al. Severe combined immunodefi ciency: a model disease for molecular immunology and therapy. Immunol Rev 2005;203:98-109.
161. Buckley RH. The multiple causes of human SCID. J Clin Invest 2004;10:1409-11.
162. Gaspar HB, Gilmour KC, Jones AM. Severe combined immunodefi-ciency: molecular pathogenesis and diagnosis. Arch Dis Child 2001;84:169-73.
163. Postigo Llorente C, Ivars Amor ós J, Ortiz de Frutos FJ et al. Cutaneous lesion in severe combined immunodefi ciency: two case reports and a review of the literature. Pediatr Dermatol 1991;8:314-21.
164. De Raeve L, Song M, Levy J et al. Cutaneous lesions as a clue to severe combined immunodefi ciency. Pediatr Dermatol 1992;9:49-51.
165. Buckley RH, Schiff SE, Schiff RI et al. Hematopoeietic stem cell transplantation for the treatment of severe combined immunodefi ciency. N Engl J Med 1999;340:508-16.
166. Haddad E, Landais P, Friedrich W et al. Long-term immune reconstitution and outcome after HLA-non identical T-cell depleted bone marrow reconstitution for severe combined immunodefi ciency, a European retrospective study of 116 patients. Blood 1998;91:3646-53.
167. Thrasher AJ. Gene therapy for primary immunodefi ciencies. Immunol Allergy Clin North Am 2008;28:457-71.
168. Flake AW, Roncarolo MG, Puck JM et al. Treatment of X-linked severe combined immunodefi ciency by in utero transplantation of paternal bone marrow. N Engl J Med 1996;335:1806-10.
169. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodefi ciency (SCID)-X1 disease. Science 2000;288:669-72.
170. Aiuti A, Slavin S, Aker M et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-3.
171. Gaspar HB, Parsley KL, Howe S et al. Gene therapy of X-linked severe combined immunodefi ciency by use of a pseudotyped gamma retroviral vector. Lancet 2004;364:2181-7.
172. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007;117:2083-6.
173. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;117:3132-42.
174. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008;15:30-6.
175. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006;117:725-38.
176. Orange JS, Stone KD, Truvey SE, Krzewski K. The Wiskott-Aldrich syndrome. Cell Mol Life Sci 2004;61:2361-85.
177. Humblet-Baron S, Sather B, Anover S et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007;117:407-18.
178. Winkelstein JA, Fearon E. Carrier detection of the X-linked primary immunodefi ciency diseases using X-chromosome inactivation analysis. J Allergy Clin Immunol 1990;85:1090-7.
179. Dupuis-Girod S, Medioni J, Haddad E et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003;111:e622-7.
180. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multi-institutional survey of Wiskott-Aldrich syndrome. J Pediatr 1994;125:876-85.
181. Conley ME, Saragoussi D, Notarangelo L et al. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol 2003;109:272-7.
182. Litzman J, Jones A, Hann I et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child 1996;75:436-9.